Tick Borne Encephalitis Inactivated Vaccine Market

ID: MRFR/Pharma/26220-HCR
100 Pages
Rahul Gotadki
Last Updated: April 06, 2026
Tick Borne Encephalitis Inactivated Vaccine Market Research Report By Dosage Type (Single Dose, Multiple Doses), By Application (Prophylaxis, Treatment), By End User (Hospitals, Clinics, Travel Medicine Facilities, Government Agencies), By Vaccine Formulation (Live Attenuated, Inactivated, Subunit, DNA/mRNA), By Distribution Channel (Wholesale Distribution, Retail Pharmacies, Online Platforms, Government Procurement) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035
Tick Borne Encephalitis Inactivated Vaccine Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)10.38%
2024 Market Size$ 416.92 Million
2025 Market Size$ 460.21 Million
2035 Market Size$ 1,235.77 Million
Key Players
Bavarian Nordic A/S
Valneva SE
Pfizer Inc.
Sanofi S.A.
GSK plc
Merck & Co.
Trends
  • Rising Awareness of Tick-Borne Diseases
  • Advancements in Vaccine Technology
  • Collaborative Public Health Initiatives
Opportunities
  • Market Growth Projections
  • Travel and Outdoor Activities
  • Advancements in Vaccine Technology
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Tick Borne Encephalitis Inactivated Vaccine Market, BY Application (USD Million)
      1. 4.1.1 Preventive Vaccination
      2. 4.1.2 Post-Exposure Prophylaxis
      3. 4.1.3 Travel Health
      4. 4.1.4 Occupational Health
    2. 4.2 Tick Borne Encephalitis Inactivated Vaccine Market, BY End Use (USD Million)
      1. 4.2.1 Hospitals
      2. 4.2.2 Clinics
      3. 4.2.3 Pharmacies
      4. 4.2.4 Public Health Organizations
    3. 4.3 Tick Borne Encephalitis Inactivated Vaccine Market, BY Distribution Channel (USD Million)
      1. 4.3.1 Direct Sales
      2. 4.3.2 Online Sales
      3. 4.3.3 Pharmaceutical Distributors
      4. 4.3.4 Healthcare Providers
    4. 4.4 Tick Borne Encephalitis Inactivated Vaccine Market, BY Formulation Type (USD Million)
      1. 4.4.1 Inactivated Virus Vaccine
      2. 4.4.2 Adjuvanted Vaccine
      3. 4.4.3 Combination Vaccine
    5. 4.5 Tick Borne Encephalitis Inactivated Vaccine Market, BY Target Population (USD Million)
      1. 4.5.1 Children
      2. 4.5.2 Adults
      3. 4.5.3 Elderly
      4. 4.5.4 Travelers
    6. 4.6 Tick Borne Encephalitis Inactivated Vaccine Market, BY Region (USD Million)
      1. 4.6.1 North America
        1. 4.6.1.1 US
        2. 4.6.1.2 Canada
      2. 4.6.2 Europe
        1. 4.6.2.1 Germany
        2. 4.6.2.2 UK
        3. 4.6.2.3 France
        4. 4.6.2.4 Russia
        5. 4.6.2.5 Italy
        6. 4.6.2.6 Spain
        7. 4.6.2.7 Rest of Europe
      3. 4.6.3 APAC
        1. 4.6.3.1 China
        2. 4.6.3.2 India
        3. 4.6.3.3 Japan
        4. 4.6.3.4 South Korea
        5. 4.6.3.5 Malaysia
        6. 4.6.3.6 Thailand
        7. 4.6.3.7 Indonesia
        8. 4.6.3.8 Rest of APAC
      4. 4.6.4 South America
        1. 4.6.4.1 Brazil
        2. 4.6.4.2 Mexico
        3. 4.6.4.3 Argentina
        4. 4.6.4.4 Rest of South America
      5. 4.6.5 MEA
        1. 4.6.5.1 GCC Countries
        2. 4.6.5.2 South Africa
        3. 4.6.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Bavarian Nordic A/S (DK)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Valneva SE (FR)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Pfizer Inc. (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Sanofi S.A. (FR)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 GSK plc (GB)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Merck & Co., Inc. (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Takeda Pharmaceutical Company Limited (JP)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 AbbVie Inc. (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports

Tick Borne Encephalitis Inactivated Vaccine Market Segmentation

Tick Borne Encephalitis Inactivated Vaccine Market By Application (USD Million, 2025-2035)

  • Preventive Vaccination
  • Post-Exposure Prophylaxis
  • Travel Health
  • Occupational Health

Tick Borne Encephalitis Inactivated Vaccine Market By End Use (USD Million, 2025-2035)

  • Hospitals
  • Clinics
  • Pharmacies
  • Public Health Organizations

Tick Borne Encephalitis Inactivated Vaccine Market By Distribution Channel (USD Million, 2025-2035)

  • Direct Sales
  • Online Sales
  • Tick Borne Encephalitis Inactivated Vaccine Market Distributors
  • Tick Borne Encephalitis Inactivated Vaccine Market Providers

Tick Borne Encephalitis Inactivated Vaccine Market By Formulation Type (USD Million, 2025-2035)

  • Inactivated Virus Vaccine
  • Adjuvanted Vaccine
  • Combination Vaccine

Tick Borne Encephalitis Inactivated Vaccine Market By Target Population (USD Million, 2025-2035)

  • Children
  • Adults
  • Elderly
  • Travelers

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.